The Motley FoolThu, 26 Mar 2026 15:33:11 GMTApogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for InvestorsAPGE+1.82%
Zacks Investment ResearchTue, 24 Mar 2026 15:31:07 GMTAPGE Stock Up as Skin Disease Drug Shows Sustained 52-Week EfficacyAPGE+1.82%
Seeking AlphaTue, 24 Mar 2026 14:54:39 GMTApogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 MilestoneAPGE+1.82%
Seeking AlphaMon, 23 Mar 2026 21:33:38 GMTApogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis TranscriptAPGE+1.82%
Seeking AlphaMon, 23 Mar 2026 21:12:56 GMTApogee Therapeutics: Two Shots A Year, One Shot At DisruptionAPGE+1.82%
BenzingaMon, 23 Mar 2026 14:04:40 GMTApogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data ReadoutAPGE+1.82%
Investors Business DailyMon, 23 Mar 2026 13:59:03 GMTHow Apogee, Up 14%, Plans To Take On Rival Regeneron's Eczema DrugAPGE+1.82%
The Motley FoolWed, 25 Feb 2026 20:06:18 GMTApogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 MillionAPGE+1.82%
The Motley FoolSun, 22 Feb 2026 18:56:14 GMTApogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing ConvictionAPGE+1.82%
The Motley FoolSat, 14 Feb 2026 15:47:32 GMTApogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 MillionAPGE+1.82%
Seeking AlphaWed, 21 Jan 2026 15:29:31 GMTApogee Therapeutics: 2026 Inflection Point In ImmunologyAPGE+1.82%
